Market open
Codexis/$CDXS
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Codexis
Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products, leveraging its proprietary CodeEvolver directed evolution technology platform. The firm's products and services include Biocatalysts and Enzymes. The company generates majority of its revenue through product sales and also licenses its technology platform CodeEvolver to pharmaceutical companies enabling them to use this technology, in-house, to engineer enzymes for their own businesses. Geographically, it derives revenue from the United States, Ireland, Switzerland, China and other markets.
Ticker
$CDXS
Sector
Trading on
Industry
Life Sciences Tools & Services
Headquarters
Employees
174
Website
Codexis Metrics
BasicAdvanced
$352M
Market cap
-
P/E ratio
-$0.88
EPS
2.07
Beta
-
Dividend rate
Price and volume
Market cap
$352M
Beta
2.07
52-week high
$4.91
52-week low
$1.85
Average daily volume
607K
Financial strength
Current ratio
3.214
Quick ratio
3.04
Long term debt to equity
51.451
Total debt to equity
57.011
Interest coverage (TTM)
-20.66%
Management effectiveness
Return on assets (TTM)
-20.95%
Return on equity (TTM)
-75.31%
Valuation
Price to revenue (TTM)
4.733
Price to book
4.8
Price to tangible book (TTM)
4.97
Price to free cash flow (TTM)
-6.613
Growth
Revenue change (TTM)
-12.86%
Earnings per share change (TTM)
-27.52%
3-year revenue growth (CAGR)
-13.99%
3-year earnings per share growth (CAGR)
55.04%
What the Analysts think about Codexis
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Codexis stock.
Codexis Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Codexis Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Codexis News
AllArticlesVideos
Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference
GlobeNewsWire·3 days ago
Codexis Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi Therapeutics
GlobeNewsWire·1 week ago
Codexis TIDES Europe Presentations to Feature Next Step in Evolution of Enzymatic Synthesis for RNAi Therapeutics
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Codexis stock?
Codexis (CDXS) has a market cap of $352M as of November 22, 2024.
What is the P/E ratio for Codexis stock?
The price to earnings (P/E) ratio for Codexis (CDXS) stock is 0 as of November 22, 2024.
Does Codexis stock pay dividends?
No, Codexis (CDXS) stock does not pay dividends to its shareholders as of November 22, 2024.
When is the next Codexis dividend payment date?
Codexis (CDXS) stock does not pay dividends to its shareholders.
What is the beta indicator for Codexis?
Codexis (CDXS) has a beta rating of 2.07. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.